You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
Maple Grove, Minnesota-based Stemonix will merge in an all-equity transaction with a newly formed subsidiary of Cancer Genetics, which expects to remain listed on the Nasdaq.
By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.
Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The newly formed company will focus on building out a precision cancer therapy-based portfolio from existing and new product candidates.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
Among Kiromic's platforms is an artificial intelligence product that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.